BioSpace News Archive

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced an agreement in principle with the United Kingdom government to establish an mRNA Innovation and Technology Center in the UK.

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced positive top line results from the exploratory, open label Phase 2 INSPIRE (Assessing the Impact of Zygel [Transdermal CBD Gel] on Pediatric Behavioral and Emotional Symptoms of 22q11.2 Deletion Syndrome) trial.

Arcturus Therapeutics Holdings Inc. announced that the Compensation Committee of the Company’s Board of Directors and the Company’s Board of Directors approved inducement grants of stock options to purchase an aggregate of 48,200 shares of Arcturus common stock to seven newly-hired employees.

Rakuten Medical Taiwan, Inc. announced that their ASP-1929 Photoimmunotherapy Phase 2 clinical trial has enrolled and treated its first patient.

Resverlogix Corp. held its Annual Meeting of Shareholders in Calgary, Alberta.

InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced that the first patient has been dosed in clinical trial of the Company’s novel SHP2 allosteric inhibitor ICP-189 in China.

The latest market analysis report published by Reports and Data, titled ‘Global Horseradish Peroxidase (HRP) Market – Forecast to 2028,’ thoroughly examines the Horseradish Peroxidase (HRP) industry to provide essential data & information for the targeted readers.